Risk-based corrosion assessment and refurbishment of marine structures

2018 ◽  
Vol 58 (1) ◽  
pp. 60
Author(s):  
Stephan Dickinson ◽  
Kerryn Wilson ◽  
Ali Sarandily ◽  
René van der Werf ◽  
Steve Sheen ◽  
...  
Keyword(s):  
Service Life ◽  
Phase 1 ◽  
Phase 2 ◽  
Remaining Life ◽  
Liquefied Petroleum Gas ◽  
Original Design ◽  
Marine Structures ◽  
Corrosion Rates ◽  
Design Life ◽  
Inspection Techniques

This paper outlines a holistic, risk-based approach to managing the service life of existing liquefied natural gas (LNG) and liquefied petroleum gas (LPG) marine structures in Western Australia. The structures have been in service since 1989 (LNG) and 1995 (LPG) and are nearing the end of their original design life. The objective of this approach is to extend the design life for an additional 20 years to 2040. The risk-based assessment (RBA) process is composed of three main steps undertaken in sequence to identify and quantify refurbishment requirements for the timeframe. A two-campaign approach was considered, the first being in 2019 (Phase 1) and the second in 2030 (Phase 2). The RBA process combines innovative and conventional inspection techniques with a detailed desktop structural assessment of the remaining life of the structures’ individual components to enable an informed decision to be made on the refurbishment requirements for each campaign. The results of the stepped RBA process demonstrate the effectiveness of the approach to define and manage a refurbishment program that achieves the required extended service life of the structures to 2040. The RBA process enabled the first campaign’s scope to be minimised through detailed analysis and calculation of residual design life of each critical member, deferring most of the refurbishment scope to the second campaign in 2030. The study has recommended implementation of a corrosion rate trial to verify the assumed corrosion rates for the jetty structures. Environmental monitoring stations and test coupons installed on the jetty for a five-year period will confirm the actual deterioration rates specific to the jetty structures. Confirmation of actual deterioration rates may reduce uncertainty in the values over those currently assumed in the study and positively affect the identified Phase 2 refurbishment scope.

The Role of Engineering Critical Assessment in the Life Extension of Risers Connected to Floating Systems

2020 ◽  
Author(s):  
Basim Mekha ◽  
Robin Gordon
Keyword(s):  
Systems Approach ◽  
Production Systems ◽  
Critical Size ◽  
Fatigue Cracks ◽  
Phase 1 ◽  
Critical Assessment ◽  
Life Extension ◽  
Original Design ◽  
Acceptance Criteria ◽  
Design Life

Abstract As many offshore production systems approach the end of their original Design Life, Operators are faced with the choice of either decommissioning or demonstrating that the original Design Life can be extended (Life Extension). Life extension requires the Operator to perform detailed engineering analyses to verify that the system can be operated safely over the period of Life Extension. In many cases this requires detailed fatigue analysis and inspection programs to demonstrate that original fabrication flaws or fatigue cracks that may have existed during the welding of the riser joints or initiated over the original Design Life will not grow to a critical size resulting in failure. Engineering Critical Assessment (ECA) is now routinely applied in the design and fabrication of new offshore riser systems to develop girth weld flaw acceptance criteria. The resulting flaw acceptance criteria ensure that fabrication flaws will not extend to a critical size over the Design Life and thus the riser still meet its calculated fatigue life. Although ECA procedures for new construction are well established and standard practices have been adopted throughout the industry, ECA procedures for Life Extension have not yet evolved to the same level of acceptance. This paper will review specific issues associated with applying ECA to support Life Extension of offshore Riser Systems. The paper will provide the overall ECA philosophy and methodology for life extension to be adopted for the historical (hindcast or Phase 1) and future (forecast or Phase 2) analysis of the risers. Some thoughts will also be given to the approach implemented to take advantage of the actual weld fabrication data with the focus on the fatigue critical sections of the risers. Finally, the paper will address the requirements for riser in-situ inspection and how the results could be analyzed and applied to the life extension analysis in conjunction with the ECA analysis.

Remaining Life Assessment and Life Extension of Offshore Pipelines

2018 ◽  
Author(s):  
Jens P. Tronskar
Keyword(s):  
Life Assessment ◽  
Life Extension ◽  
Remaining Life ◽  
Original Design ◽  
Offshore Pipelines ◽  
Field Development ◽  
Design Life ◽  
The Future ◽  
Cost Efficient ◽  
Remaining Life Assessment

Cost efficient offshore field development often involves tiebacks to existing field infrastructure. Efficient field development requires life extension of existing production facilities and pipelines to accommodate the new field resources over their life expectation. For fields near the tail end of their production the pipelines may be close to the end of their design life, and it must be shown that they have potential for extended life beyond the original design life until the end of the period of operation of the new field. Offshore pipelines are designed and constructed to recognized standards, such as the widely applied DNV OS-F101 2013 Submarine Pipelines Systems and earlier versions. The latest edition of the code was recently issued as a standard with some major updates and a modified code number i.e. DNVGL ST-F101 [1]. As pipelines age, they will inevitably be exposed to various types of degradation and an Operator must be able to both assess the significance of this damage and the pipeline remaining life to ensure that the pipelines do not fail as they age before the end of their design lives. Currently, many pipelines are operated far beyond the original design life and as mentioned above for cost efficient field development the pipeline operator often needs to demonstrate that the pipeline’s useful life can be extended another 10 or in some cases up to 30 years. For some pipelines, new operating conditions will be introduced by tie-in of new fields and this will impact the future rate of degradation. Hence, it cannot be assumed that the future degradation will be similar or less severe than experienced since commissioning of the pipeline. Extension of the life of the pipeline can be demonstrated by adopting methods of analysis that show the line is safe for an extended life under the future expected operating condition. This paper describes the risk based approach applied for pipeline remaining life and life extension analyses based on DNV GL codes and other relevant recommended practices. For illustration of the methodology a typical case of remaining life assessment of and life extension of a gas export pipeline is presented in the Case Study.

Rationalization and internalization

2001 ◽  
Vol 60 (4) ◽  
pp. 215-230 ◽  
Author(s):  
Jean-Léon Beauvois
Keyword(s):  
Phase 1 ◽  
Facilitatory Effect ◽  
Phase 2 ◽  
Causal Explanations ◽  
Reduction Effect ◽  
Dissonance Reduction

After having been told they were free to accept or refuse, pupils aged 6–7 and 10–11 (tested individually) were led to agree to taste a soup that looked disgusting (phase 1: initial counter-motivational obligation). Before tasting the soup, they had to state what they thought about it. A week later, they were asked whether they wanted to try out some new needles that had supposedly been invented to make vaccinations less painful. Agreement or refusal to try was noted, along with the size of the needle chosen in case of agreement (phase 2: act generalization). The main findings included (1) a strong dissonance reduction effect in phase 1, especially for the younger children (rationalization), (2) a generalization effect in phase 2 (foot-in-the-door effect), and (3) a facilitatory effect on generalization of internal causal explanations about the initial agreement. The results are discussed in relation to the distinction between rationalization and internalization.

PENERAPAN MODEL QUANTUM LEARNING UNTUK MENINGKATKAN HASIL BELAJAR AUTOCAD SISWA KELAS X TEKNIK PEMESINAN SMK NEGERI 1 STABAT

2013 ◽  
Vol 5 (1) ◽  
Author(s):  
Abdul Hasan Saragih
Keyword(s):  
Positive Response ◽  
Phase 1 ◽  
First Grade ◽  
Learning Model ◽  
Second Phase ◽  
Phase 2 ◽  
Phase 3 ◽  
The Third ◽  
Third Phase ◽  
Quantum Learning

This classroom research was conducted on the autocad instructions to the first grade of mechinary class of SMK Negeri 1 Stabat aiming at : (1) improving the student’ archievementon autocad instructional to the student of mechinary architecture class of SMK Negeri 1 Stabat, (2) applying Quantum Learning Model to the students of mechinary class of SMK Negeri 1 Stabat, arising the positive response to autocad subject by applying Quantum Learning Model of the students of mechinary class of SMK Negeri 1 Stabat. The result shows that (1) by applying quantum learning model, the students’ achievement improves significantly. The improvement ofthe achievement of the 34 students is very satisfactory; on the first phase, 27 students passed (70.59%), 10 students failed (29.41%). On the second phase 27 students (79.41%) passed and 7 students (20.59%) failed. On the third phase 30 students (88.24%) passed and 4 students (11.76%) failed. The application of quantum learning model in SMK Negeri 1 Stabat proved satisfying. This was visible from the activeness of the students from phase 1 to 3. The activeness average of the students was 74.31% on phase 1,81.35% on phase 2, and 83.63% on phase 3. (3) The application of the quantum learning model on teaching autocad was very positively welcome by the students of mechinary class of SMK Negeri 1 Stabat. On phase 1 the improvement was 81.53% . It improved to 86.15% on phase 3. Therefore, The improvement ofstudent’ response can be categorized good.

In situ deteriorating patient simulation in general practice

2020 ◽  
Vol 70 (suppl 1) ◽  
pp. bjgp20X711425
Author(s):  
Joanna Lawrence ◽  
Petronelle Eastwick-Field ◽  
Anne Maloney ◽  
Helen Higham
Keyword(s):  
Life Support ◽  
Early Recognition ◽  
Phase 1 ◽  
Patient Simulation ◽  
Medical Emergency ◽  
Phase 2 ◽  
Action Plans ◽  
Integrated Simulation ◽  
Deteriorating Patient

BackgroundGP practices have limited access to medical emergency training and basic life support is often taught out of context as a skills-based event.AimTo develop and evaluate a whole team integrated simulation-based education, to enhance learning, change behaviours and provide safer care.MethodPhase 1: 10 practices piloted a 3-hour programme delivering 40 minutes BLS and AED skills and 2-hour deteriorating patient simulation. Three scenarios where developed: adult chest pain, child anaphylaxis and baby bronchiolitis. An adult simulation patient and relative were used and a child and baby manikin. Two facilitators trained in coaching and debriefing used the 3D debriefing model. Phase 2: 12 new practices undertook identical training derived from Phase 1, with pre- and post-course questionnaires. Teams were scored on: team working, communication, early recognition and systematic approach. The team developed action plans derived from their learning to inform future response. Ten of the 12 practices from Phase 2 received an emergency drill within 6 months of the original session. Three to four members of the whole team integrated training, attended the drill, but were unaware of the nature of the scenario before. Scoring was repeated and action plans were revisited to determine behaviour changes.ResultsEvery emergency drill demonstrated improved scoring in skills and behaviour.ConclusionA combination of: in situ GP simulation, appropriately qualified facilitators in simulation and debriefing, and action plans developed by the whole team suggests safer care for patients experiencing a medical emergency.

Clinical Drug Development for the Treatment of Pulmonary Arterial Hypertension: Collaboration With the Pharmaceutical Industry and Regulatory Agencies

2010 ◽  
Vol 9 (4) ◽  
pp. 214-219
Author(s):  
Robyn J. Barst
Keyword(s):  
Clinical Trials ◽  
Pulmonary Arterial Hypertension ◽  
Drug Development ◽  
Phase 1 ◽  
Preclinical Studies ◽  
Phase 2 ◽  
Phase 3 ◽  
Preclinical Testing ◽  
New Drug ◽  
Pulmonary Arterial

Drug development is the entire process of introducing a new drug to the market. It involves drug discovery, screening, preclinical testing, an Investigational New Drug (IND) application in the US or a Clinical Trial Application (CTA) in the EU, phase 1–3 clinical trials, a New Drug Application (NDA), Food and Drug Administration (FDA) review and approval, and postapproval studies required for continuing safety evaluation. Preclinical testing assesses safety and biologic activity, phase 1 determines safety and dosage, phase 2 evaluates efficacy and side effects, and phase 3 confirms efficacy and monitors adverse effects in a larger number of patients. Postapproval studies provide additional postmarketing data. On average, it takes 15 years from preclinical studies to regulatory approval by the FDA: about 3.5–6.5 years for preclinical, 1–1.5 years for phase 1, 2 years for phase 2, 3–3.5 years for phase 3, and 1.5–2.5 years for filing the NDA and completing the FDA review process. Of approximately 5000 compounds evaluated in preclinical studies, about 5 compounds enter clinical trials, and 1 compound is approved (Tufts Center for the Study of Drug Development, 2011). Most drug development programs include approximately 35–40 phase 1 studies, 15 phase 2 studies, and 3–5 pivotal trials with more than 5000 patients enrolled. Thus, to produce safe and effective drugs in a regulated environment is a highly complex process. Against this backdrop, what is the best way to develop drugs for pulmonary arterial hypertension (PAH), an orphan disease often rapidly fatal within several years of diagnosis and in which spontaneous regression does not occur?

scholarly journals A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas

Cancer ◽  
2019 ◽  
Vol 125 (14) ◽  
pp. 2445-2454 ◽  
Author(s):  
Robin L. Jones ◽  
Sant P. Chawla ◽  
Steven Attia ◽  
Patrick Schöffski ◽  
Hans Gelderblom ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Phase 1 ◽  
Soft Tissue Sarcomas ◽  
Phase 2 ◽  
Safety And Efficacy ◽  
Randomized Controlled ◽  
Phase 2 Trial

scholarly journals Quantitative Checklist for Autism in Toddlers (Q-CHAT). A population screening study with follow-up: the case for multiple time-point screening for autism

2021 ◽  
Vol 5 (1) ◽  
pp. e000700
Author(s):  
Carrie Allison ◽  
Fiona E Matthews ◽  
Liliana Ruta ◽  
Greg Pasco ◽  
Renee Soufer ◽  
...  
Keyword(s):  
Phase 1 ◽  
Autism Spectrum ◽  
Population Screening ◽  
Diagnostic Assessment ◽  
Test Accuracy ◽  
Multiple Time ◽  
Phase 2 ◽  
Time Points ◽  
Screening Study

ObjectiveThis is a prospective population screening study for autism in toddlers aged 18–30 months old using the Quantitative Checklist for Autism in Toddlers (Q-CHAT), with follow-up at age 4.DesignObservational study.SettingLuton, Bedfordshire and Cambridgeshire in the UK.Participants13 070 toddlers registered on the Child Health Surveillance Database between March 2008 and April 2009, with follow-up at age 4; 3770 (29%) were screened for autism at 18–30 months using the Q-CHAT and the Childhood Autism Spectrum Test (CAST) at follow-up at age 4.InterventionsA stratified sample across the Q-CHAT score distribution was invited for diagnostic assessment (phase 1). The 4-year follow-up included the CAST and the Checklist for Referral (CFR). All with CAST ≥15, phase 1 diagnostic assessment or with developmental concerns on the CFR were invited for diagnostic assessment (phase 2). Standardised diagnostic assessment at both time-points was conducted to establish the test accuracy of the Q-CHAT.Main outcome measuresConsensus diagnostic outcome at phase 1 and phase 2.ResultsAt phase 1, 3770 Q-CHATs were returned (29% response) and 121 undertook diagnostic assessment, of whom 11 met the criteria for autism. All 11 screened positive on the Q-CHAT. The positive predictive value (PPV) at a cut-point of 39 was 17% (95% CI 8% to 31%). At phase 2, 2005 of 3472 CASTs and CFRs were returned (58% response). 159 underwent diagnostic assessment, including 82 assessed in phase 1. All children meeting the criteria for autism identified via the Q-CHAT at phase 1 also met the criteria at phase 2. The PPV was 28% (95% CI 15% to 46%) after phase 1 and phase 2.ConclusionsThe Q-CHAT can be used at 18–30 months to identify autism and enable accelerated referral for diagnostic assessment. The low PPV suggests that for every true positive there would, however, be ~4–5 false positives. At follow-up, new cases were identified, illustrating the need for continued surveillance and rescreening at multiple time-points using developmentally sensitive instruments. Not all children who later receive a diagnosis of autism are detectable during the toddler period.

scholarly journals Evaluation of health system readiness and coverage of intermittent preventive treatment of malaria in infants (IPTi) in Kambia district to inform national scale-up in Sierra Leone

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Maria Lahuerta ◽  
Roberta Sutton ◽  
Anthony Mansaray ◽  
Oliver Eleeza ◽  
Brigette Gleason ◽  
...  
Keyword(s):  
Sierra Leone ◽  
Phase 1 ◽  
Scale Up ◽  
Intermittent Preventive Treatment ◽  
Vaccine Dose ◽  
Preventive Treatment ◽  
Household Survey ◽  
Register Data ◽  
Phase 2 ◽  
Pentavalent Vaccine

Abstract Background Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP) is a proven strategy to protect infants against malaria. Sierra Leone is the first country to implement IPTi nationwide. IPTi implementation was evaluated in Kambia, one of two initial pilot districts, to assess quality and coverage of IPTi services. Methods This mixed-methods evaluation had two phases, conducted 3 (phase 1) and 15–17 months (phase 2) after IPTi implementation. Methods included: assessments of 18 health facilities (HF), including register data abstraction (phases 1 and 2); a knowledge, attitudes and practices survey with 20 health workers (HWs) in phase 1; second-generation sequencing of SP resistance markers (pre-IPTi and phase 2); and a cluster-sample household survey among caregivers of children aged 3–15 months (phase 2). IPTi and vaccination coverage from the household survey were calculated from child health cards and maternal recall and weighted for the complex sampling design. Interrupted time series analysis using a Poisson regression model was used to assess changes in malaria cases at HF before and after IPTi implementation. Results Most HWs (19/20) interviewed had been trained on IPTi; 16/19 reported feeling well prepared to administer it. Nearly all HFs (17/18 in phase 1; 18/18 in phase 2) had SP for IPTi in stock. The proportion of parasite alleles with dhps K540E mutations increased but remained below the 50% WHO-recommended threshold for IPTi (4.1% pre-IPTi [95%CI 2–7%]; 11% post-IPTi [95%CI 8–15%], p < 0.01). From the household survey, 299/459 (67.4%) children ≥ 10 weeks old received the first dose of IPTi (versus 80.4% for second pentavalent vaccine, given simultaneously); 274/444 (62.5%) children ≥ 14 weeks old received the second IPTi dose (versus 65.4% for third pentavalent vaccine); and 83/217 (36.4%) children ≥ 9 months old received the third IPTi dose (versus 52.2% for first measles vaccine dose). HF register data indicated no change in confirmed malaria cases among infants after IPTi implementation. Conclusions Kambia district was able to scale up IPTi swiftly and provide necessary health systems support. The gaps between IPTi and childhood vaccine coverage need to be further investigated and addressed to optimize the success of the national IPTi programme.

Monte-Carlo interpretation of the JANUS Phase 1, Phase 2 and Phase 4 shielding experiments with TRIPOLI-4®

2021 ◽  
Vol 159 ◽  
pp. 108333
Author(s):  
Amine Hajji ◽  
Christine Coquelet-Pascal ◽  
Patrick Blaise
Keyword(s):  
Monte Carlo ◽  
Phase 1 ◽  
Phase 2
Sign in / Sign up

Export Citation Format

Share Document